Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk is one the best bets in Big Pharma with its focus on diabetes and obesity. Its focus on diabetes and obesity should ensure a strong pipeline for the next decade. Novo Nordisk has a minimum 4 year runway to grow with its strong line up of patent protected diabetes and obesity drugs.

Novo Nordisk, A Very Healthy Pharma Stalwart

AerCap Hlds

ARM Holdings PLC

Alphabet

Jacobs Solutions Inc

Splunk

WisdomTree U.S. Earnings 500 Fund

George Soros stocks will always remain relevant for savvy investors. As one of the most successful financiers in history, George Soros's investment strategies attract a massive audience worldwide.

What Would George Soros Do? 7 Stocks the Billionaire's Fund Bought & Sold in Q4

Eli Lilly

A rival's weight-loss drug candidate did well in a mid-stage clinical trial. The treatment met all of its endpoints in the study.

Why Novo Nordisk and Eli Lilly Stocks Slipped Today

Celsius Holdings

Walmart

Many stock splits have occurred in recent years, with companies aiming to increase liquidity within shares and erase barriers to entry for potential investors. Lower share prices are more affordable for a greater portion of investors, although it's worth noting that the rise of fractional share investing has alleviated this issue for some.

Stock Splits: Should You Buy?

Broadcom

LVMH Moet Hennessy Louis Vuitton

Tesla

Taiwan Semiconductor Manufacturing

Investors learned an important lesson in 2023: investing in the biggest companies and their stocks is a surefire way to capture strong gains. The Magnificent 7 – all of which are trillion dollar stocks – produced strong returns for investors.

Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now

NVIDIA

The Ozempic and GLP-1 weight loss trend parallels the artificial intelligence (AI) mania that's gone mainstream viral, sending stocks like Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ: NVDA through the roof. While GLP-1 users report amazing weight loss results, like Oprah Winfrey losing 60 pounds, users continue to report the side effects of nausea, vomiting, gastrointestinal maladies and the return of weight once getting off the treatment.

These 2 carnivore dining stocks gaining on the Ozempic craze

Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

Novo Nordisk and Eli Lilly rival soars 26% after promising weight-loss drug results

Novo Nordisk's shares are climbing thanks to its latest hit medicines. That's making financial analysts raise their expectations for its stock.

1 Wall Street Analyst Thinks Novo Nordisk Stock Is Going to $140. Is It a Buy?

Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar.

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

ASML Hld

Growing demand for megacap stocks that tap global secular growth trends has catapulted European shares to fresh highs, although some say their star may wane as investors seek value elsewhere.

Europe's megacap appeal stokes stocks to record highs

AstraZeneca

L'Oreal SA

Nestle SA

Roche Holding AG

SAP SE

GlaxoSmithKline

Novartis

Sanofi

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Move Over Magnificent 7, Say Hello to the GRANOLAS

Regeneron Pharmaceuticals

Novo Nordisk continues to innovate exactly where it counts. Regeneron's key growth drivers still have lots of room to run.

2 No-Brainer Biotech Stocks to Buy Right Now

Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application.

Notice for the Annual General Meeting of Novo Nordisk A/S

Equinix

Intuitive Surgical

Onto Innovation

UiPath

Rockwell Automation

Top sectors are tough to pin down in advance. Far more often, we look backward at market performance to identify trends and top sectors.

3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024

BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases. Almirall will accelerate the development.

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology

While Ozempic is often affiliated with weight loss, the drug is not approved by the FDA for such a use. But its sibling treatment, Wegovy, is approved for chronic weight management in obesity patients.

Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.

Caterpillar

First Solar

In the fast-paced world of investing, growth stocks stand out as promising candidates to build wealth. These companies can grow their revenue and earnings at a much faster pace than their competition.

Wealth Generators: 3 Growth Stocks You'll Regret Not Buying in 2024

U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks.

Eli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost

The feverish craze for Wegovy, Ozempic and other GLP-1 drugs is not over. It is prompting food executives to call the top boss at Novo Nordisk to ask for advice.

Novo Nordisk CEO says food execs are ‘scared' of weight loss drug threat

Visa

Finding the next trillion-dollar companies isn't easy, but it doesn't have to be difficult. While tempting, avoid the urge to pick a handful of small-cap tech stocks or growth stocks that you think may be worth $1 trillion or more in the future.

Meet the Next Trillion-Dollar Companies: Our Top 7 Picks

Novo Nordisk's weight loss drug, Wegovy, shows potential for reducing cardiovascular risks by 20% in overweight or obese individuals. The company is actively working to scale up production of Wegovy to meet increasing demand and decrease cost per unit. Novo Nordisk's partnerships with Regeneron Pharmaceuticals, Omega Therapeutics, and Cellarity demonstrate their commitment to innovative treatments for cardiometabolic diseases.

Novo Nordisk: These Bold Moves Point Toward Upside

Amgen

DexCom

Pfizer

Viking Therapeutics

It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.

7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution

Top weight-loss treatment Wegovy generated 400% revenue growth for Novo Nordisk in 2023. The drug can, however, cost patients without insurance coverage more than $16,000 per year.

1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year

Amgen is the latest big pharma to join the gold rush to treat obesity. Its candidate is distinct from the medicines by Eli Lilly and Novo Nordisk.

Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?

Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.

Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.

News for Novo Nordisk Stock (NVO)